Literature DB >> 15821216

Safety and tolerability of nonbronchoscopic lavage in ARDS.

Gavin D Perkins1, Somnath Chatterjee, Simon Giles, Danny F McAuley, Sarah Quinton, David R Thickett, Fang Gao.   

Abstract

STUDY
OBJECTIVE: This study compared the safety profiles of bronchoscopic lavage with nonbronchoscopic lavage in the investigation of patients with acute lung injury (ALI) or ARDS.
DESIGN: Single-center, randomized, cross-over study.
SETTING: General ICU in the United Kingdom. PARTICIPANTS: Fourteen patients with ALI or ARDS.
INTERVENTIONS: Bronchoscopic BAL and nonbronchoscopic BAL 1 h apart. MEASUREMENTS AND
RESULTS: Hemodynamic and ventilatory parameters were recorded during and for 1 h following each procedure. On average, bronchoscopic lavage took longer to perform than nonbronchoscopic lavage (7 min and 6 s vs 2 min and 28 s, p < 0.001). During the procedures, bronchoscopic lavage increased heart rate and systolic BP more than nonbronchoscopic lavage (23% vs 10% [p < 0.01] and 18% vs 7% [p < 0.01]). Three patients had ST-segment depression during bronchoscopic, and one patient had ST-segment depression during nonbronchoscopic lavage (p = 0.298). Bronchoscopic lavage reduced minute ventilation by 63 +/- 17.3%, while nonbronchoscopic lavage only reduced it by 36 +/- 21.9% (p < 0.001). Paco(2) rose more after bronchoscopic lavage than after nonbronchoscopic lavage.
CONCLUSION: Nonbronchoscopic lavage is associated with less marked physiologic derangements than bronchoscopic lavage. Further studies are required to validate the hypothesis that nonbronchoscopic lavage may be safer in patients with unstable coronary heart disease or head injury/raised intracranial pressure who are at risk from unpredictable fluctuations in hemodynamic and ventilatory profiles.

Entities:  

Mesh:

Year:  2005        PMID: 15821216     DOI: 10.1378/chest.127.4.1358

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Diagnostic strategy in cancer patients with acute respiratory failure.

Authors:  Elie Azoulay; Benoît Schlemmer
Journal:  Intensive Care Med       Date:  2006-04-29       Impact factor: 17.440

2.  Non-directed bronchial lavage is a safe method for sampling the respiratory tract in critically ill patient.

Authors:  B V Bonvento; J A Rooney; M O Columb; B A McGrath; A M Bentley; T W Felton
Journal:  J Intensive Care Soc       Date:  2018-11-13

3.  Non-bronchoscopic Bronchoalveolar Lavage as a Refinement for Safely Obtaining High-quality Samples from Macaques.

Authors:  Cassandra R Moats; Kurt T Randall; Tonya M Swanson; Hugh B Crank; Kimberly M Armantrout; Aaron M Barber-Axthelm; Nicole D Burnett; Theodore R Hobbs; Lauren D Martin; Roxanne M Gilbride; Scott Hansen; Jeremy V Smedley
Journal:  Comp Med       Date:  2020-11-05       Impact factor: 0.982

4.  Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia.

Authors:  Rogier M Determann; Julian L Millo; Sébastien Gibot; Johanna C Korevaar; Margreeth B Vroom; Tom van der Poll; Christopher S Garrard; Marcus J Schultz
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

Review 5.  Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients.

Authors:  Elizabeth Foglia; Mary Dawn Meier; Alexis Elward
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

6.  The Beta Agonist Lung Injury TrIal (BALTI)--prevention trial protocol.

Authors:  Gavin D Perkins; Daniel Park; Derek Alderson; Matthew W Cooke; Fang Gao; Simon Gates; Sarah E Lamb; Dipesh Mistry; David R Thickett
Journal:  Trials       Date:  2011-03-15       Impact factor: 2.279

7.  New Delhi metallo-β-lactamase-producing Acinetobacter isolates among late-onset VAP patients: multidrug-resistant pathogen and poor outcome.

Authors:  Asmaa M Elbrolosy; Azza Z Labeeb; Dina M Hassan
Journal:  Infect Drug Resist       Date:  2019-02-11       Impact factor: 4.003

8.  Effectiveness of biomarker-based exclusion of ventilator-acquired pneumonia to reduce antibiotic use (VAPrapid-2): study protocol for a randomised controlled trial.

Authors:  Thomas P Hellyer; Niall H Anderson; Jennie Parker; Paul Dark; Tina Van Den Broeck; Suveer Singh; Ronan McMullan; Ashley M Agus; Lydia M Emerson; Bronagh Blackwood; Savita Gossain; Tim S Walsh; Gavin D Perkins; Andrew Conway Morris; Daniel F McAuley; A John Simpson
Journal:  Trials       Date:  2016-07-16       Impact factor: 2.279

9. 

Authors:  L Camous; V Lemiale; D Schnell; S de Miranda; E Azoulay
Journal:  Rev Malad Respir Actual       Date:  2010-04-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.